Search

Your search keyword '"van der Heijde, D."' showing total 2,588 results

Search Constraints

Start Over You searched for: Author "van der Heijde, D." Remove constraint Author: "van der Heijde, D."
2,588 results on '"van der Heijde, D."'

Search Results

3. POS0011 FACTORS ASSOCIATED WITH THE EVOLUTION OF DEGENERATIVE SPINAL LESIONS IN AXIAL SPONDYLOARTHRITIS: 10-YEAR FOLLOW-UP OF THE DESIR COHORT

4. OP0021 3-YEAR RESULTS OF TAPERING TNFi TO WITHDRAWAL COMPARED TO STABLE TNFi AMONG RHEUMATOID ARTHRITIS PATIENTS IN SUSTAINED REMISSION: A MULTICENTER RANDOMIZED TRIAL

5. POS0005 A TWO-YEAR COMPARISON OF BACK PAIN AND MORNING STIFFNESS BETWEEN AXIAL SPONDYLOARTHRITIS AND CHRONIC BACK PAIN PATIENTS IN THE SPONDYLOARTHRITIS CAUGHT EARLY (SPACE) COHORT

7. POS0503 PREDICTIVE VALIDITY OF DATA-DRIVEN DEFINITIONS FOR ACTIVE AND STRUCTURAL LESIONS IN THE SI JOINTS TYPICAL FOR AXIAL SPA: A 2-YEAR FOLLOW-UP IN THE SPONDYLOARTHRITIS CAUGHT EARLY COHORT

8. POS0222 ASDAS RESPONSES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS STARTING BDMARDS: RESULTS FROM A MULTICENTRE PROSPECTIVE COHORT

9. POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES

10. POS0050 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR DATA FROM THE PHASE 3 SELECT-AXIS 2 STUDY

12. POS0510 A TWO-YEAR COMPARISON OF SPINAL AND HIP MOBILITY BETWEEN AXIAL SPONDYLOARTHRITIS AND CHRONIC BACK PAIN PATIENTS IN THE SPONDYLOARTHRITIS CAUGHT EARLY (SPACE) COHORT

13. OP0310 HOW EARLY IS EARLY? UNVEILING TIME TO DIAGNOSIS SINCE SYMPTOM ONSET AND ITS DETERMINANTS IN PATIENTS SUSPECTED OF EARLY AXIAL SPONDYLOARTHRITIS: DATA FROM THE SPONDYLOARTHRITIS CAUGHT EARLY (SPACE) COHORT

15. POS1381 NATURAL COURSE OF DEGENERATIVE CHANGES OF THE SPINE ON RADIOGRAPHS AND MRI IN AXIAL SPONDYLOARTHRITIS FOLLOWED 10 YEARS IN THE DESIR COHORT

16. POS0215 LONG-TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 5-YEAR RESULTS FROM A PHASE 2B STUDY AND ITS OPEN-LABEL EXTENSION

17. POS0798 EFFICACY, SAFETY AND RADIOGRAPHIC OUTCOMES FROM THE PHASE 3 SELECT-AXIS 2 STUDY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND AN INADEQUATE RESPONSE TO BIOLOGIC DMARD THERAPY: 2-YEAR DATA

18. The ASAS-OMERACT core domain set for axial spondyloarthritis

19. Le bimékizumab permet le maintien des réponses cliniques évaluées par des critères stricts jusqu’à la semaine 52 chez les patients atteints de spondyloarthrite axiale : résultats des études de phase III BE MOBILE 1 et BE MOBILE 2

20. Tolérance et efficacité à long terme du bimékizumab chez les patients atteints de spondylarthrite ankylosante active : résultats à 5 ans d’une étude de phase IIb et de son extension en ouvert

21. Effet du sécukinumab versus adalimumab biosimilaire sur la progression radiographique chez les patients atteints de spondyloarthrite axiale radiographique : analyse en sous-groupes avec sur le statut syndesmophytes et protéine C-réactive à l’inclusion

22. Effet du sécukinumab versus adalimumab biosimilaire sur la progression radiographique chez les patients atteints de spondyloarthrite axiale radiographique : étude randomisée de phase 3b

25. POS1122 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND AN INADEQUATE RESPONSE TO BIOLOGIC DMARD THERAPY: ONE-YEAR RESULTS FROM A PHASE 3 STUDY

28. POS0181 THE IMPACT OF AUTOANTIBODIES (RF AND ACPA) ON THE EFFICACY OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

29. POS1104 BIMEKIZUMAB MAINTAINED STRINGENT CLINICAL RESPONSES THROUGH WEEK 52 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2

30. OP0005 CAN AXIAL SPONDYLOARTHRITIS UNEQUIVOCALLY BE DIAGNOSED BY RHEUMATOLOGISTS IN PATIENTS WITH CHRONIC BACK PAIN OF LESS THAN TWO YEARS DURATION? MAIN RESULT OF THE SPONDYLOARTHRITIS CAUGHT EARLY (SPACE) COHORT

33. POS0250 PLACEBO-CONTROLLED EFFICACY AND SAFETY OF UPADACITINIB THROUGH ONE YEAR IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS

34. OP0059 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB BIOSIMILAR ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A RANDOMISED PHASE IIIB STUDY

36. OP0055 ASAS CONSENSUS DEFINITION OF EARLY AXIAL SPONDYLOARTHRITIS

39. POS0049 CLINICAL AND RADIOGRAPHIC RESULTS OF TAPERING AND WITHDRAWING CSDMARDS VERSUS STABLE TREATMENT IN RHEUMATOID ARTHRITIS REMISSION: 3-YEAR RESULTS FROM A RANDOMIZED CONTROLLED TRIAL

40. OP0054 THE YIELD OF REPEATED ASSESSMENTS IN CHRONIC BACK PAIN PATIENTS SUSPECTED OF EARLY AXIAL SPONDYLOARTHRITIS: TWO-YEAR DATA FROM THE SPONDYLOARTHRITIS CAUGHT EARLY (SPACE) COHORT

41. POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES

43. Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis

48. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

49. Amélioration des signes et symptômes chez des patients atteints de spondyloarthrite axiale radiographique traités par bimékizumab : résultats à 24 semaines d’une étude de phase III, multicentrique, randomisée et contrôlée par placebo

50. Efficacité et tolérance d’upadacitinib chez des patients atteints de spondylarthrite ankylosante et ayant eu une intolérance et/ou un manque d’efficacité lors d’un traitement antérieur par biologique : analyse en sous-groupes

Catalog

Books, media, physical & digital resources